BD
MCID: BHC003
MIFTS: 71

Behcet Syndrome (BD)

Categories: Bone diseases, Cardiovascular diseases, Eye diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Behcet Syndrome

MalaCards integrated aliases for Behcet Syndrome:

Name: Behcet Syndrome 56 12 74 52 25 43 37 71
Behcet's Syndrome 12 52 25 29 6 42 17
Behcet Disease 56 25 58 36 54
Behcet's Disease 12 52 53 15
Behçet Disease 52 25 32
Adamantiades-Behcet Disease 12 25
Triple Symptom Complex 12 25
Bd 56 52
Behcet Triple Symptom Complex 25
Old Silk Route Disease 25
Malignant Aphthosis 25
Behcet Disease; Bd 56
Behçet's Syndrome 52
Behet's Syndrome 12
Behçet's Disease 52
Syndrome, Behcet 39
Behçet Syndrome 52
Bd Syndrome 52

Characteristics:

Orphanet epidemiological data:

58
behcet disease
Inheritance: Multigenic/multifactorial; Prevalence: 1-5/10000 (Japan),>1/1000 (Turkey); Age of onset: Adolescent,Adult,Childhood; Age of death: adult;

OMIM:

56
Inheritance:
familial cases reported, but probably not mendelian


HPO:

31
behcet syndrome:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases
Rare circulatory system diseases
Rare renal diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Summaries for Behcet Syndrome

Genetics Home Reference : 25 Behçet disease is an inflammatory condition that affects many parts of the body. The health problems associated with Behçet disease result from widespread inflammation of blood vessels (vasculitis). This inflammation most commonly affects small blood vessels in the mouth, genitals, skin, and eyes. Painful mouth sores called aphthous ulcers are usually the first sign of Behçet disease. These sores can occur on the lips, tongue, inside the cheeks, the roof of the mouth, the throat, and the tonsils. The ulcers look like common canker sores, and they typically heal within one to two weeks. About 75 percent of all people with Behçet disease develop similar ulcers on the genitals. These ulcers occur most frequently on the scrotum in men and on the labia in women. Behçet disease can also cause painful bumps and sores on the skin. Most affected individuals develop pus-filled bumps that resemble acne. These bumps can occur anywhere on the body. Some affected people also have red, tender nodules called erythema nodosum. These nodules usually develop on the legs but can also occur on the arms, face, and neck. An inflammation of the eye called uveitis is found in more than half of people with Behçet disease. Eye problems are more common in younger people with the disease and affect men more often than women. Uveitis can result in blurry vision and an extreme sensitivity to light (photophobia). Rarely, inflammation can also cause eye pain and redness. If untreated, the eye problems associated with Behçet disease can lead to blindness. Joint involvement is also common in Behçet disease. Often this affects one joint at a time, with each affected joint becoming swollen and painful and then getting better. Less commonly, Behçet disease can affect the brain and spinal cord (central nervous system), gastrointestinal tract, large blood vessels, heart, lungs, and kidneys. Central nervous system abnormalities can lead to headaches, confusion, personality changes, memory loss, impaired speech, and problems with balance and movement. Involvement of the gastrointestinal tract can lead to a hole in the wall of the intestine (intestinal perforation), which can cause serious infection and may be life-threatening. The signs and symptoms of Behçet disease usually begin in a person's twenties or thirties, although they can appear at any age. Some affected people have relatively mild symptoms that are limited to sores in the mouth and on the genitals. Others have more severe symptoms affecting various parts of the body, including the eyes and the vital organs. The features of Behçet disease typically come and go over a period of months or years. In most affected individuals, the health problems associated with this disorder improve with age.

MalaCards based summary : Behcet Syndrome, also known as behcet's syndrome, is related to uveitis and chlamydia, and has symptoms including edema, pruritus and chest pain. An important gene associated with Behcet Syndrome is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Fluocinolone Acetonide and Omega 3 Fatty Acid have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and brain, and related phenotypes are arthritis and photophobia

Disease Ontology : 12 A vasculitis that is characterized by an autoimmune mediated inflammation of the blood vessels throughout the body leading to ulcerations on the mouth and sometimes the genitals, notorious for causing hypopyon uveitis.

NIH Rare Diseases : 52 Behcet disease is a chronic multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. In some people, the disease also results in arthritis (swollen, painful, stiff joints), skin problems, and inflammation of the digestive tract, brain, and spinal cord. Although it can happen at any age, symptoms generally begin when individuals are in their 20s or 30s. The disease is common in Japan, Turkey and Israel, and less common in the United States. The exact cause of Behcet disease is still unknown, but it is thought that it is an autoimmune disease , where the abnormal immune activity is triggered by exposure to an environmental agent (such as an infection) in people with a genetic predisposition to develop the disease. Research show that people with Behcet's disease, especially those of Middle Eastern and Asian descent, have an increased frequency of certain "human leukocyte antigens " (HLAs), specifically HLA-B51, than the general population, which may increase the risk (predispose) to have the disease. Treatment is symptomatic and supportive. Research is being conducted on the use of interferon-alpha and with agents which inhibit tumor necrosis factor (TNF) for the treatment of Behcet disease. Behcet disease is a lifelong disorder that comes and goes. Spontaneous remission over time is common for individuals with Behcet disease but permanent remission of symptoms has not been reported.

MedlinePlus : 42 Behcet's syndrome is a disease that involves vasculitis, which is inflammation of the blood vessels. It causes problems in many parts of the body. The most common symptoms are Sores in the mouth Sores on the sex organs Other skin sores Swelling of parts of the eye Pain, swelling and stiffness of the joints More serious problems can include meningitis, blood clots, inflammation of the digestive system and blindness. Doctors aren't sure what causes Behcet's. It is rare in the United States, but is common in the Middle East and Asia. It mainly affects people in their 20s and 30s. Diagnosing Behcet's can take a long time, because symptoms may come and go, and it may take months or even years to have all of the symptoms. There is no cure. Treatment focuses on reducing pain and preventing serious problems. Most people can control symptoms with treatment. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 53 Behcet's disease is a rare, chronic inflammatory disorder. The cause of Behcet's disease is unknown, but current research suggests that both genetic and  environmental factors play a role.  Behcet's disease generally begins when individuals are in their 20s or 30s, although it can happen at any age. It tends to occur more often in men than in women. Symptoms of Behcet's disease include recurrent ulcers in the mouth (resembling canker sores) and on the genitals, and eye inflammation. The disorder may also cause various types of skin lesions, arthritis, bowel inflammation, meningitis (inflammation of the membranes of the brain and spinal cord), and cranial nerve palsies. Behcet's is a multi-system disease; it may involve all organs and affect the central nervous system, causing memory loss and impaired speech, balance, and movement. The effects of the disease may include blindness, stroke, swelling of the spinal cord, and intestinal complications. The disease is common in the Middle East, particularly in Turkey, and in Far Eastern nations such as Japan and Korean, but is less common in the United States.

KEGG : 36 Behcet disease is a multisystemic inflammatory disease characterized by relapsing episodes of oral aphthous ulcers, genital ulcers, other skin lesions, and uveitis. It can also involve visceral organs such as the gastrointestinal tract, pulmonary, musculoskeletal, cardiovascular and neurological systems. This disease is more common in countries along the ancient Silk Road, including Asia, Middle East, and Mediterranean. Although the etiology is still unknown, this disease is believed to be triggered by environmental factors such as microbial agents in individuals with a particular genetic background. The positive association of HLA-B51 was identified more than four decades ago, and has been confirmed in multiple populations. Recent genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet disease.

Wikipedia : 74 Behçet's disease (BD) is a type of inflammatory disorder which affects multiple parts of the body. The... more...

More information from OMIM: 109650

Related Diseases for Behcet Syndrome

Diseases related to Behcet Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1184)
# Related Disease Score Top Affiliating Genes
1 uveitis 32.4 TNFRSF1A TNF RBP3 NOD2 IL10 HLA-B
2 chlamydia 32.1 TNF TLR4 IL10 CRP
3 spondyloarthropathy 1 32.0 TNFRSF1A TNF TLR4 NOD2 IL23R HLA-B
4 arthritis 31.8 TNFRSF1A TNF TLR4 STAT4 PSTPIP1 NOD2
5 iridocyclitis 31.7 TNF RBP3 IL10 HLA-B CRP
6 vogt-koyanagi-harada disease 31.7 TLR4 IL10 HLA-B FAS
7 exanthem 31.7 TNF MEFV IL10 CRP
8 pyoderma 31.7 TNF PSTPIP1 NOD2 MEFV CRP
9 systemic lupus erythematosus 31.7 TNFRSF1A TNF TLR4 STAT4 IL10 FAS
10 pyoderma gangrenosum 31.7 TNF PSTPIP1 NOD2 MEFV
11 rheumatoid arthritis 31.6 TNFRSF1A TNF TLR4 STAT4 IL23R IL10
12 familial mediterranean fever 31.6 TNFRSF1A TNF TLR4 PSTPIP1 NOD2 MEFV
13 enthesopathy 31.6 TNF MEFV ERAP1 CRP
14 intestinal perforation 31.6 TNF TLR4 NOD2 CRP
15 crohn's disease 31.6 TNFRSF1A TNF TLR4 NOD2 IL23R IL10
16 pericarditis 31.6 TNFRSF1A TNF MEFV CRP
17 iritis 31.6 TNF RBP3 NOD2 HLA-B ERAP1 CRP
18 hypopyon 31.5 UBAC2 TNF RBP3 IL10 HLA-B CRP
19 colitis 31.5 TNF TLR4 NOD2 IL23R IL10
20 brucellosis 31.5 TNF TLR4 MEFV IL10 CRP
21 diarrhea 31.5 TNF TLR4 NOD2 MEFV IL10
22 psoriasis 31.5 TNFRSF1A TNF NOD2 IL23R IL10 HLA-B
23 vasculitis 31.5 TNF MEFV IL10 HLA-B CRP
24 bacterial vaginosis 31.5 TNF TLR4 IL10
25 pustulosis of palm and sole 31.5 TNF PSTPIP1 CRP
26 myelitis 31.5 TNFRSF1A TNF IL10
27 inflammatory bowel disease 31.5 TNFRSF1A TNF TLR4 STAT4 PSTPIP1 NOD2
28 vaginitis 31.5 TNF TLR4 IL10
29 chickenpox 31.5 TNF IL10 CRP
30 pharyngitis 31.4 TNF MEFV CRP
31 lymphadenitis 31.4 TNF TLR4 NOD2 IL10 FAS CRP
32 peritonitis 31.4 TNF TLR4 MEFV IL10 CRP
33 myocarditis 31.4 TNF TLR4 IL10 HLA-B
34 psoriatic arthritis 31.4 TNFRSF1A TNF TLR4 NOD2 IL23R IL10
35 dysentery 31.4 TNF TLR4 IL10 CRP
36 autoimmune uveitis 31.4 TNF STAT4 RBP3 IL10
37 autoimmune disease 31.4 TNFRSF1A TNF STAT4 RBP3 IL23R IL10
38 eye disease 31.4 TNF TLR4 RBP3 IL10 CRP
39 celiac disease 1 31.4 TNF TLR4 STAT4 NOD2 IL23R IL10
40 tonsillitis 31.4 TNF TLR4 IL10
41 meningoencephalitis 31.4 TNF IL10 CRP
42 thrombocytopenia 31.4 TNFRSF1A TNF TLR4 IL10 HLA-B FAS
43 panuveitis 31.3 TNF RBP3 IL23R IL10 HLA-B ERAP1
44 aplastic anemia 31.3 TNF STAT4 IL23R IL12A IL10 HLA-B
45 aphthous stomatitis 31.3 TNF TLR4 MEFV IL10 HLA-B CCR1
46 ulcerative colitis 31.3 TNF TLR4 NOD2 IL23R IL10 CRP
47 juvenile rheumatoid arthritis 31.3 TNFRSF1A TNF STAT4 IL10 CRP
48 spondylarthropathy 31.3 TNFRSF1A TNF TLR4 NOD2
49 urethritis 31.3 TNF TLR4 CRP
50 proteasome-associated autoinflammatory syndrome 1 31.3 TNF TLR4 MEFV IL10 CRP

Graphical network of the top 20 diseases related to Behcet Syndrome:



Diseases related to Behcet Syndrome

Symptoms & Phenotypes for Behcet Syndrome

Human phenotypes related to Behcet Syndrome:

58 31 (show top 50) (show all 81)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001369
2 photophobia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000613
3 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
4 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
5 subcutaneous nodule 58 31 hallmark (90%) Very frequent (99-80%) HP:0001482
6 papule 58 31 hallmark (90%) Very frequent (99-80%) HP:0200034
7 nausea and vomiting 58 31 hallmark (90%) Very frequent (99-80%) HP:0002017
8 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
9 migraine 58 31 hallmark (90%) Very frequent (99-80%) HP:0002076
10 meningitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001287
11 vasculitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002633
12 orchitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100796
13 oral ulcer 58 31 hallmark (90%) Very frequent (99-80%) HP:0000155
14 recurrent aphthous stomatitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0011107
15 gait disturbance 58 31 frequent (33%) Frequent (79-30%) HP:0001288
16 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
17 abnormal blistering of the skin 58 31 frequent (33%) Frequent (79-30%) HP:0008066
18 acne 58 31 frequent (33%) Frequent (79-30%) HP:0001061
19 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
20 gastrointestinal hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0002239
21 venous thrombosis 58 31 frequent (33%) Frequent (79-30%) HP:0004936
22 immunologic hypersensitivity 58 31 frequent (33%) Frequent (79-30%) HP:0100326
23 hemiparesis 58 31 frequent (33%) Frequent (79-30%) HP:0001269
24 confusion 58 31 frequent (33%) Frequent (79-30%) HP:0001289
25 cataract 58 31 occasional (7.5%) Occasional (29-5%) HP:0000518
26 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
27 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
28 avascular necrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0010885
29 malabsorption 58 31 occasional (7.5%) Occasional (29-5%) HP:0002024
30 developmental regression 58 31 occasional (7.5%) Occasional (29-5%) HP:0002376
31 blindness 58 31 occasional (7.5%) Occasional (29-5%) HP:0000618
32 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
33 retinopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000488
34 cranial nerve paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006824
35 abnormal pyramidal sign 58 31 occasional (7.5%) Occasional (29-5%) HP:0007256
36 irritability 58 31 occasional (7.5%) Occasional (29-5%) HP:0000737
37 ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001251
38 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
39 hyperreflexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001347
40 abnormal myocardium morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0001637
41 myocardial infarction 58 31 occasional (7.5%) Occasional (29-5%) HP:0001658
42 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
43 pulmonary infiltrates 58 31 occasional (7.5%) Occasional (29-5%) HP:0002113
44 memory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002354
45 myositis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100614
46 gangrene 58 31 occasional (7.5%) Occasional (29-5%) HP:0100758
47 mitral regurgitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0001653
48 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
49 vertigo 58 31 occasional (7.5%) Occasional (29-5%) HP:0002321
50 glomerulopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0100820

Symptoms via clinical synopsis from OMIM:

56
Joints:
arthritis

Skin:
raynaud phenomenon
superficial thrombophlebitis
hyperirritability
erythema nodosum-like eruptions
pustular skin lesions

G U:
epididymitis
genital ulcerations

Neuro:
brainstem syndrome
meningoencephalomyelitic syndrome
organic confusional state
schizoaffective disorder

Eyes:
hypopyon
uveitis
iridocyclitis
iritis
choreoretinitis

Hair:
alopecia areata

Mouth:
mouth ulcerations

Clinical features from OMIM:

109650

UMLS symptoms related to Behcet Syndrome:


edema, pruritus, chest pain, angina pectoris, snoring, halitosis, exanthema, oral manifestations

GenomeRNAi Phenotypes related to Behcet Syndrome according to GeneCards Suite gene sharing:

26 (show all 49)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 10.02 NOD2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-113 10.02 TLR4
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 10.02 TLR4
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 10.02 IL10
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 10.02 IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 10.02 TLR4
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.02 IL10
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-174 10.02 NOD2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.02 NOD2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.02 IL10
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 10.02 CRP
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 10.02 NOD2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-192 10.02 NOD2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-195 10.02 NOD2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 10.02 IL10
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.02 IL10
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.02 NOD2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.02 CRP
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.02 CRP NOD2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.02 NOD2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-80 10.02 IL10
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 10.02 CRP
23 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.78 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.78 CCR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.78 CCR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.78 C4A
27 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.78 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.78 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.78 TLR4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.78 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.78 C4A IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.78 CCR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.78 IL10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.78 IL10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 IL10
36 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.78 TLR4
37 Increased shRNA abundance (Z-score > 2) GR00366-A-33 9.78 CCR1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.78 CCR1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.78 C4A
40 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.78 IL10
41 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.78 IL10
42 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.78 CCR1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.78 C4A
44 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.78 IL10
45 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.78 IL10
46 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.78 IL10 TLR4
47 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.78 C4A
48 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.78 IL10
49 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 IL10

MGI Mouse Phenotypes related to Behcet Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 CCR1 ERAP1 FAS IL10 IL12A IL23R
2 digestive/alimentary MP:0005381 9.86 CCR1 FAS IL10 IL23R NOD2 TLR4
3 immune system MP:0005387 9.8 CCR1 CRP ERAP1 FAS IL10 IL12A
4 neoplasm MP:0002006 9.17 FAS IL10 IL12A IL23R TLR4 TNF

Drugs & Therapeutics for Behcet Syndrome

Drugs for Behcet Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
2 Omega 3 Fatty Acid Phase 4
3
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
4
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
5
leucovorin Approved Phase 3 58-05-9 6006 143
6
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
7
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
8
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
9 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
10
Adalimumab Approved Phase 3 331731-18-1 16219006
11
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
12
Ethanol Approved Phase 3 64-17-5 702
13
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
14
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
15
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
16
Colchicine Approved Phase 3 64-86-8 2833 6167
17
Infliximab Approved Phase 3 170277-31-3
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
20 Methylprednisolone Acetate Phase 3
21 Vitamin B Complex Phase 3
22 Folic Acid Antagonists Phase 3
23 Folate Phase 3
24 Antimetabolites Phase 3
25 Vitamin B9 Phase 3
26 Interferon-beta Phase 3
27 Narcotics Phase 3
28 Narcotic Antagonists Phase 3
29 Anti-Infective Agents Phase 3
30 interferons Phase 3
31 Interferon-alpha Phase 3
32 Antiviral Agents Phase 3
33 Interferon alpha-2 Phase 3
34 Cyclosporins Phase 3
35 Antifungal Agents Phase 3
36 Anti-Bacterial Agents Phase 3
37 Angiogenesis Inhibitors Phase 3
38 Analgesics, Non-Narcotic Phase 3
39 Analgesics Phase 3
40 Anti-Inflammatory Agents, Non-Steroidal Phase 3
41 Tubulin Modulators Phase 3
42 Antimitotic Agents Phase 3
43 Immunoglobulin A Phase 3
44 Dermatologic Agents Phase 3
45 Gastrointestinal Agents Phase 3
46 Antirheumatic Agents Phase 3
47 Pharmaceutical Solutions Phase 3
48
rituximab Approved Phase 2 174722-31-7 10201696
49
Azathioprine Approved Phase 2 446-86-6 2265
50
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
2 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
3 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
4 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
5 An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease Completed NCT02505568 Phase 3 Infliximab
6 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
7 A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Completed NCT01243671 Phase 3
8 Efficacy of Humira in Behcet Patients With Arthritis Completed NCT01497717 Phase 3 Adalimumab (Humira)
9 To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650 Completed NCT01532570 Phase 3 TA-650
10 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
11 A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM) Completed NCT00344253 Phase 3 Interferon beta;Methotrexate
12 Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis. Completed NCT00720538 Phase 3 Thalidomide;placebo
13 A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54) Completed NCT00501696 Phase 3 4.5 mg Naltrexone;Naltrexone
14 Randomized Prospective Comparative Study of Interferon α2a and Cyclosporine in Patients With Refractory Behçet`s Disease Uveitis Recruiting NCT03209219 Phase 3 Interferon Alfa-2A;Cyclosporine Pill
15 Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
16 A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease Active, not recruiting NCT02307513 Phase 3 Apremilast;Placebo
17 Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Not yet recruiting NCT03371095 Phase 3 Infliximab;Cyclophosphamide
18 Evaluation of Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis Not yet recruiting NCT04008316 Phase 3 Colchicine
19 A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis Terminated NCT02258867 Phase 3 Placebo;Gevokizumab
20 A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis Terminated NCT01965145 Phase 3 Gevokizumab;Placebo
21 A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study Terminated NCT02375685 Phase 3
22 An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US) Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
23 Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-Over, 32 Weeks Study Terminated NCT00505947 Phase 3 infliximab;placebo
24 An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease Unknown status NCT03522662 Phase 2 GSK1070806
25 An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behçet's Disease Patients With Neurologic or Vascular Involvement Completed NCT02756650 Phase 2 Canakinumab
26 Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study) Completed NCT00664599 Phase 2 Rituximab;Cytotoxic Combination
27 A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast(CC-10004) in the Treatment of Behçet Disease Completed NCT00866359 Phase 2 Apremilast (CC-10004);Placebo
28 A Double Blind Cross Over Clinical Trial to Determine Colchicine Efficacy in Behcet`s Disease Completed NCT00700297 Phase 2 Colchicine;Placebo
29 A Study to Investigate the Safety and Efficacy of HAT to Treat the Ocular Complications Related to Behcet's Disease Completed NCT00001865 Phase 2 Daclizumab
30 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
31 Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease Completed NCT00483184 Phase 2
32 A Pilot Study of Anakinra in Behcet's Disease (BD) Completed NCT01441076 Phase 1, Phase 2 Anakinra
33 Evaluation of Birdshot RETINE CHOROIDOPATHY Treatment by Either Steroid or Interferon alpha2a Completed NCT00508040 Phase 2 interferon alpha 2a;prednisone
34 Ilaris (Canakinumab) in the Schnitzler Syndrome. A Case Series. Completed NCT01245127 Phase 2 Ilaris
35 Clinical Protocol for Administration of Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers Recruiting NCT03888846 Phase 2 Pentoxifylline;Colchicine
36 Efficacy and Safety of Golimumab in the Treatment of Refractory Uveitis in Patients With Behcet's Disease Recruiting NCT04218565 Phase 2
37 Efficacy and Safety of Tocilizumab in the Treatment of Refractory Uveitis in Patients With Behcet's Disease Recruiting NCT03554161 Phase 2
38 Low-dose IL-2 Treatment on Behcet's Disease Recruiting NCT04065672 Phase 2 Low-dose IL-2
39 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Recruiting NCT01988506 Phase 2 Interleukin 2
40 A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Active, not recruiting NCT02648581 Phase 2 Subcutaneous Ustekinumab
41 Clinical Protocol to Evaluate Use of Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers Not yet recruiting NCT04186559 Phase 2 Topical Pentoxifylline Gel (Vehicle +PTX);Topical Placebo Gel (Vehicle)
42 Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose Suspended NCT02494492 Phase 1, Phase 2
43 Tocilizumab for the Treatment of Behcet's Syndrome Terminated NCT01693653 Phase 2 Tocilizumab
44 A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD) Withdrawn NCT01211977 Phase 1, Phase 2 XOMA 052
45 Phase 1 Study of Bone Marrow - Derived Stem Cell in the Treatment of Ocular Lesions of Behcet's Disease Terminated NCT00550498 Phase 1
46 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
47 Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease Unknown status NCT00931957 Etanercept, Methotrexate, Prednisolone
48 Non-infectious and Infectious Uveitis Diagnosis Unknown status NCT02627209
49 Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses Unknown status NCT01952275
50 Evaluation of Fibromyalgia With Disease Activity and Clinical Findings in Women With Behçet's Disease in Province Bursa Completed NCT03543709

Search NIH Clinical Center for Behcet Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Behcet Syndrome cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Behcet Syndrome:
Bone marrow-derived stem cells for treatment of ocular lesions Behcet's disease
Embryonic/Adult Cultured Cells Related to Behcet Syndrome:
Bone marrow-derived stem cells PMIDs: 23773637 21199472

Cochrane evidence based reviews: behcet syndrome

Genetic Tests for Behcet Syndrome

Genetic tests related to Behcet Syndrome:

# Genetic test Affiliating Genes
1 Behcet's Syndrome 29

Anatomical Context for Behcet Syndrome

MalaCards organs/tissues related to Behcet Syndrome:

40
Skin, Eye, Brain, Spinal Cord, Lung, Kidney, Tongue

Publications for Behcet Syndrome

Articles related to Behcet Syndrome:

(show top 50) (show all 687)
# Title Authors PMID Year
1
Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. 56 54
9037047 1997
2
A family study of Behcet's syndrome. 56 61
718279 1978
3
Behcet's syndrome with neurological manifestations in two sisters. 56 61
4296824 1968
4
Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. 56
28166214 2017
5
Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. 56
23396137 2013
6
Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. 56
23291587 2013
7
Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. 56
20622878 2010
8
Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. 56
20622879 2010
9
Proteomic surveillance of autoimmunity in Behcet's disease with uveitis: selenium binding protein is a novel autoantigen in Behcet's disease. 56
17343851 2007
10
Comparison of patients with Behçet's disease in the 1980s and 1990s. 56
15051217 2004
11
Identification of an autosomal recessive mode of inheritance in paediatric Behçet's families by segregation analysis. 56
12955762 2003
12
Conjunctival ulcers in Behçet's disease. 56
12799237 2003
13
Serum leptin concentration is increased in patients with Behçet's syndrome and is correlated with disease activity. 56
12174107 2002
14
Localization of the pathogenic gene of Behçet's disease by microsatellite analysis of three different populations. 56
11053265 2000
15
Familial aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probands. 56
10393610 1999
16
Genetic analysis of families of patients with Behçet's syndrome: data incompatible with autosomal recessive inheritance. 56
3707215 1986
17
Familial cases of Behcet's disease. 56
4063168 1985
18
Close association of HLA-Bw51 with Behçet's disease. 56
6956266 1982
19
Familial Behçet's syndrome. 56
1009010 1976
20
Behçet's syndrome with arthritis. 56
5777255 1969
21
Familial recurrent orogenital ulceration. 56
13823878 1960
22
Diagnostic value of hemoglobin and neutrophil-to-lymphocyte ratio in Behcet Disease. 42
31876725 2019
23
Decreased Level of IL-37 Correlates Negatively with Inflammatory Cytokines in Cerebrospinal Fluid of Patients with Neuro-Behcet's Disease. 42
31885007 2019
24
Epigenetics and Behçet's Disease: DNA Methylation Specially Highlighted. 42
32245289 2019
25
Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. 61 54
15823500 2005
26
[Concentration of procalcitonin and C-reactive protein in serum and erythrocyte sedimentation rate in active autoimmune diseases in children]. 61 54
14648981 2003
27
A human T-cell receptor recognizes 'O'-linked sugars from the hinge region of human IgA1 and IgD. 54 61
7821975 1994
28
Management of Behcet's syndrome. 61
32348509 2020
29
Sexual dysfunction in Behçet's syndrome. 61
31595309 2020
30
[Clinical characteristics analysis of 1 808 rheumatism in-patients with oral candidiasis]. 61
31874483 2019
31
A Study to Assess The Efficacy of Local Application of Oral Probiotic in Treating Recurrent Aphthous Ulcer and Oral Candidiasis. 61
31741944 2019
32
Synbiotic Supplementation May Relieve Anterior Uveitis, an Ocular Manifestation in Behcet's Syndrome. 61
31000688 2019
33
[Pseudo-tumor form of neuro-Behçet disease: case study and literature review]. 61
31692738 2019
34
HLAs in Autoimmune Diseases: Dependable Diagnostic Biomarkers? 61
30644346 2019
35
An Unusual Cause of Fever. 61
31313562 2018
36
Penile pyoderma gangrenousm treated with cyclosporine: Case report. 61
30317330 2018
37
Surgical treatment of intestinal perforation in Behçet Syndrome: an unusual presentation. 61
30574248 2018
38
Behcet's Syndrome: Fear Not the Unknown. 61
30236452 2018
39
Concurrent presence of buccal mucosal and ophthalmologic lesions in Behcet's syndrome. 61
30510645 2018
40
Is Warfarin Indicated in Behcet's Syndrome Associated with Thrombosis? Reflections on Treatment and Death of a Patient. 61
29271390 2018
41
Qualitative study: the experience and impact of living with Behcet's syndrome. 61
28934765 2017
42
To immunosuppress or not: Behcet's syndrome presenting as an eosinophilic pleural effusion. 61
28869232 2017
43
Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis. 61
28447207 2017
44
Behcet's syndrome in nonendemic regions. 61
27684358 2017
45
[Clinical effect analysis of endovascular repair for aortic pseudoaneurysms in 13 cases]. 61
28088958 2017
46
Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. 61
26392009 2016
47
Giant Pulmonary Artery Aneurysm in Behcet's Syndrome. 61
27645984 2016
48
Hypopyon complicating the course of anterior uveitis in a patient with Behcet's syndrome. 61
27648274 2016
49
Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center. 61
27100417 2016
50
Delayed Vasospasm after Aneurysmal Subarachnoid Hemorrhage in Behcet Syndrome. 61
27114963 2016

Variations for Behcet Syndrome

ClinVar genetic disease variations for Behcet Syndrome:

6 (show all 17) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MEFV NM_000243.2(MEFV):c.1211A>G (p.His404Arg)SNV Pathogenic 375252 rs755659290 16:3299480-3299480 16:3249480-3249480
2 MEFV NM_000243.2(MEFV):c.1099C>G (p.Leu367Val)SNV Pathogenic 375253 rs1057519328 16:3299592-3299592 16:3249592-3249592
3 NOD2 NM_022162.2(NOD2):c.2197G>T (p.Val733Leu)SNV Pathogenic 267319 rs746055479 16:50746019-50746019 16:50712108-50712108
4 TNFRSF1A NM_001065.3(TNFRSF1A):c.463C>T (p.His155Tyr)SNV Pathogenic 267318 rs886039866 12:6442542-6442542 12:6333376-6333376
5 NOD2 NM_022162.2(NOD2):c.2446G>ASNV Pathogenic 267317 rs886040969 16:50746268-50746268 16:50712357-50712357
6 NOD2 NM_022162.3(NOD2):c.1045C>T (p.Leu349Phe)SNV Pathogenic 268134 rs752615209 16:50744867-50744867 16:50710956-50710956
7 MEFV NM_000243.2(MEFV):c.332G>A (p.Gly111Glu)SNV Pathogenic 430715 rs751454741 16:3304736-3304736 16:3254736-3254736
8 PSTPIP1 NM_003978.5(PSTPIP1):c.865G>C (p.Asp289His)SNV Pathogenic 280942 rs774164456 15:77325229-77325229 15:77032888-77032888
9 TNFRSF1A NM_001065.4(TNFRSF1A):c.935G>A (p.Arg312Lys)SNV Conflicting interpretations of pathogenicity 378735 rs200900510 12:6439066-6439066 12:6329900-6329900
10 ADA2 NM_001282225.2(ADA2):c.927G>A (p.Met309Ile)SNV Conflicting interpretations of pathogenicity 375247 rs146597836 22:17670877-17670877 22:17189987-17189987
11 ADA2 NM_001282225.2(ADA2):c.740C>T (p.Ala247Val)SNV Uncertain significance 375251 rs750868279 22:17684466-17684466 22:17203576-17203576
12 TNFRSF1A NM_001065.3(TNFRSF1A):c.596T>C (p.Ile199Thr)SNV Uncertain significance 234423 rs104895247 12:6440048-6440048 12:6330882-6330882
13 PSTPIP1 NM_003978.5(PSTPIP1):c.364G>A (p.Val122Ile)SNV Uncertain significance 280941 rs886041107 15:77320202-77320202 15:77027861-77027861
14 ADA2 NM_001282225.2(ADA2):c.145C>T (p.Arg49Trp)SNV Uncertain significance 375246 rs199614299 22:17690423-17690423 22:17209533-17209533
15 NOD2 NM_022162.2(NOD2):c.241C>G (p.Leu81Val)SNV Likely benign 267320 rs34936594 16:50733566-50733566 16:50699655-50699655
16 ADA2 NM_001282225.2(ADA2):c.1045G>A (p.Val349Ile)SNV Benign/Likely benign 430693 rs74317375 22:17669265-17669265 22:17188375-17188375
17 PSTPIP1 NM_003978.5(PSTPIP1):c.203C>T (p.Thr68Met)SNV Benign/Likely benign 317171 rs201872851 15:77310863-77310863 15:77018522-77018522

Copy number variations for Behcet Syndrome from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 241985 8 6835170 6856724 Copy number DEFA1 Behcet''s disease

Expression for Behcet Syndrome

Search GEO for disease gene expression data for Behcet Syndrome.

Pathways for Behcet Syndrome

Pathways related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TNFRSF1A TNF TLR4 PSTPIP1 NOD2 MEFV
2
Show member pathways
13.34 TNFRSF1A TNF TLR4 STAT4 IL23R IL12A
3
Show member pathways
13.32 TNFRSF1A TNF NOD2 IL23R IL12A IL10
4
Show member pathways
13.28 TNFRSF1A TNF IL23R IL12A IL10 FAS
5
Show member pathways
13 TNFRSF1A TNF TLR4 STAT4 IL12A IL10
6
Show member pathways
12.91 TNFRSF1A TNF TLR4 HLA-B FAS CCR1
7
Show member pathways
12.78 TNFRSF1A TNF TLR4 IL12A HLA-B FAS
8 12.77 TNFRSF1A TNF IL12A HLA-B FAS
9
Show member pathways
12.76 TNF KLRC4 IL12A IL10 HLA-B FAS
10
Show member pathways
12.59 TNF TLR4 PSTPIP1 IL10 FAS
11
Show member pathways
12.56 TNFRSF1A TNF TLR4 IL12A FAS
12 12.54 TNFRSF1A TNF STAT4 IL10 FAS
13
Show member pathways
12.45 TNF TLR4 STAT4 NOD2 IL23R IL12A
14
Show member pathways
12.43 STAT4 IL23R IL12A IL10 CCR1
15
Show member pathways
12.31 TNFRSF1A TNF IL10 CCR1
16 12.25 TNFRSF1A TNF TLR4 FAS
17
Show member pathways
12.2 TNFRSF1A TNF TLR4 IL12A IL10
18 12.17 TNF TLR4 PSTPIP1 NOD2 MEFV
19
Show member pathways
12.12 TNFRSF1A TNF TLR4 STAT4 FAS
20 12.05 TNFRSF1A TNF TLR4 NOD2 IL12A IL10
21 11.99 TNF TLR4 MEFV IL10
22 11.96 TNF IL23R IL12A IL10
23 11.93 TNFRSF1A TNF NOD2 FAS
24 11.89 TNF TLR4 IL12A IL10
25
Show member pathways
11.82 TLR4 STAT4 IL23R
26
Show member pathways
11.77 TNFRSF1A TNF FAS
27 11.75 TNF IL23R IL12A IL10
28 11.72 TNF IL12A IL10
29 11.59 TNF TLR4 IL12A
30 11.57 TNFRSF1A TNF TLR4
31 11.54 TNFRSF1A TNF FAS
32 11.54 TNF TLR4 IL12A IL10 C4A
33 11.51 TNF TLR4 IL12A
34 11.46 TNFRSF1A TNF FAS
35 11.46 TNF TLR4 IL12A IL10
36
Show member pathways
11.46 TNF TLR4 STAT4 IL23R IL12A IL10
37 11.34 TNF TLR4 IL10
38 11.27 TNF IL12A IL10 FAS
39 11.24 TNFRSF1A TNF IL12A IL10 CCR1
40 11.1 TNFRSF1A TNF NOD2
41
Show member pathways
10.58 TNFRSF1A TNF IL12A IL10 FAS

GO Terms for Behcet Syndrome

Cellular components related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 TNFRSF1A TNF RBP3 IL12A IL10 ERAP1
2 extracellular region GO:0005576 9.81 TNFRSF1A TNF RBP3 IL12A IL10 FAS
3 external side of plasma membrane GO:0009897 9.35 TNF TLR4 IL23R FAS CCR1
4 cell surface GO:0009986 9.17 TNFRSF1A TNF TLR4 NOD2 IL12A HLA-B

Biological processes related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 TNF TLR4 NOD2 CCR1
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.92 TNFRSF1A TNF TLR4 NOD2
3 defense response to bacterium GO:0042742 9.92 TNFRSF1A TNF TLR4 NOD2 IL10
4 immune system process GO:0002376 9.92 TLR4 PSTPIP1 NOD2 MEFV IL23R HLA-B
5 immune response GO:0006955 9.91 TNF TLR4 IL12A IL10 HLA-B FAS
6 response to lipopolysaccharide GO:0032496 9.9 TLR4 IL23R IL12A IL10
7 positive regulation of inflammatory response GO:0050729 9.87 TNFRSF1A TNF TLR4
8 regulation of inflammatory response GO:0050727 9.87 TNF TLR4 NOD2
9 positive regulation of JNK cascade GO:0046330 9.85 TNF TLR4 NOD2
10 cellular response to mechanical stimulus GO:0071260 9.85 TNFRSF1A TLR4 FAS
11 apoptotic signaling pathway GO:0097190 9.83 TNF TLR4 FAS
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.83 TNFRSF1A TNF TLR4
13 cellular response to lipopolysaccharide GO:0071222 9.83 TNF TLR4 NOD2 IL12A IL10
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 TNF TLR4 NOD2
15 defense response GO:0006952 9.8 TNFRSF1A TNF STAT4 NOD2 HLA-B
16 positive regulation of interleukin-6 production GO:0032755 9.79 TNF TLR4 NOD2
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 TNFRSF1A TNF IL23R IL12A
18 innate immune response GO:0045087 9.76 TLR4 PSTPIP1 NOD2 MEFV IL23R HLA-B
19 interleukin-12-mediated signaling pathway GO:0035722 9.75 STAT4 IL12A IL10
20 extrinsic apoptotic signaling pathway GO:0097191 9.74 TNF IL12A FAS
21 negative regulation of interleukin-6 production GO:0032715 9.73 TNF TLR4 IL10
22 positive regulation of interleukin-8 production GO:0032757 9.71 TNF TLR4 NOD2
23 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.69 TNF TLR4
24 positive regulation of ceramide biosynthetic process GO:2000304 9.69 TNFRSF1A TNF
25 positive regulation of T cell mediated cytotoxicity GO:0001916 9.69 IL23R IL12A HLA-B
26 negative regulation of interleukin-12 production GO:0032695 9.68 MEFV IL10
27 detection of bacterium GO:0016045 9.68 NOD2 HLA-B
28 interleukin-35-mediated signaling pathway GO:0070757 9.68 STAT4 IL12A
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 TLR4 IL10
30 negative regulation of lipid storage GO:0010888 9.67 TNF CRP
31 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.67 TNF TLR4 NOD2
32 interleukin-23-mediated signaling pathway GO:0038155 9.66 STAT4 IL23R
33 regulation of establishment of endothelial barrier GO:1903140 9.65 TNFRSF1A TNF
34 positive regulation of osteoclast differentiation GO:0045672 9.65 TNF IL23R CCR1
35 necroptotic signaling pathway GO:0097527 9.64 TNF FAS
36 endothelial cell apoptotic process GO:0072577 9.64 TNF IL10
37 death-inducing signaling complex assembly GO:0071550 9.63 TNFRSF1A TNF
38 positive regulation of lymphocyte proliferation GO:0050671 9.63 TLR4 IL12A
39 negative regulation of cytokine production involved in immune response GO:0002719 9.61 TNF IL10
40 positive regulation of NK T cell activation GO:0051135 9.59 IL23R IL12A
41 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 TNF IL10
42 positive regulation of interferon-gamma production GO:0032729 9.56 TNF TLR4 IL23R IL12A
43 receptor biosynthetic process GO:0032800 9.55 TNF IL10
44 cytokine-mediated signaling pathway GO:0019221 9.5 TNFRSF1A TNF STAT4 IL23R IL12A IL10
45 inflammatory response GO:0006954 9.28 TNFRSF1A TNF TLR4 PSTPIP1 MEFV IL23R

Molecular functions related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 TNF TLR4 STAT4 PSTPIP1 MEFV FAS
2 tumor necrosis factor-activated receptor activity GO:0005031 9.16 TNFRSF1A FAS
3 complement component C1q binding GO:0001849 8.96 CRP C4A
4 interleukin-12 receptor binding GO:0005143 8.62 IL23R IL12A

Sources for Behcet Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....